Human leukocyte antigen class I-presented HIV-1 clade B epitope (HLA-I HIV-1 B epitope)

Human leukocyte antigen (HLA) class I-presented HIV-1 B clade epitopes are short peptide fragments, typically 8-11 amino acids long, derived from the proteome of the HIV-1 subtype B virus (NIH, 2023). These peptides are processed intracellularly and loaded onto HLA class I molecules for presentation on the surface of infected cells, where they serve as the primary targets for CD8+ cytotoxic T lymphocytes (CTLs) (PubMed, 2021). In HIV-1 clade B, which is the predominant subtype in North America and Europe, specific epitopes from proteins such as Gag, Pol, and Nef are critical for immune surveillance and viral control (LANL HIV Database, 2024). Therapeutic strategies targeting these epitopes include the development of TCR-engineered T cells, bispecific T-cell engagers like ImmTAVs, and therapeutic vaccines designed to enhance or redirect the immune response toward conserved viral regions (Immunocore, 2022). However, the high mutation rate of HIV-1 often leads to viral escape, where mutations within these epitopes prevent HLA binding or TCR recognition, posing a significant challenge for long-term efficacy (PubMed, 2019). Furthermore, the effectiveness of these therapies is restricted to patients carrying specific HLA alleles, such as HLA-A*02:01, which are required to present the target epitope to the immune system (Frontiers in Immunology, 2021).

Other names

HIV-1 clade B HLA-I restricted peptidesMHC class I-presented HIV-1 B clade antigensHIV-1 B clade CTL epitopesHIV-1 subtype B HLA class I epitopes

Recognition of the peptide-HLA complex by specific T-cell receptors (TCRs) triggers the activation of cytotoxic T lymphocytes, leading to the targeted lysis of HIV-infected cells and the secretion of antiviral cytokines such as IFN-gamma and TNF-alpha (PubMed, 2021).